Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader

被引:17
|
作者
Zhu, Cheng-Liang [2 ,4 ,7 ]
Luo, Xiaomin [1 ]
Tian, Tian [3 ]
Rao, Zijian [2 ]
Wang, Hanlin [10 ]
Zhou, Zhesheng [2 ]
Mi, Tian [5 ]
Chen, Danni [2 ]
Xu, Yongjin [9 ]
Wu, Yizhe
Che, Jinxin [3 ]
Zhou, Yubo [1 ,5 ,6 ]
Li, Jia [1 ,5 ,6 ]
Dong, Xiaowu [3 ,7 ,8 ]
机构
[1] Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
[2] Zhejiang Univ, Inst Pharmacol & Toxicol, Coll Pharmaceut Sci, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou 310058, Peoples R China
[3] Zhejiang Univ, Hangzhou Inst Innovat Med, Inst Drug Discovery & Design, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China
[4] Ctr Drug Safety Evaluat & Res ZJU, Hangzhou 310058, Peoples R China
[5] Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, State Key Lab Drug Res, Shanghai 201203, Peoples R China
[6] Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan Tsuihang New Di 528400, Guangdon, Peoples R China
[7] Zhejiang Univ, Innovat Inst Artificial Intelligence Med, Hangzhou 310016, Peoples R China
[8] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Peoples R China
[9] Canc Hosp Univ Chinese Acad Sci, Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc, Hangzhou 310005, Peoples R China
[10] Fudan Univ, Sch Pharm, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
AKT; Protein kinase B; PROTAC; Chemical degrader; Rational design; MANTLE CELL LYMPHOMA; BIOLOGICAL EVALUATION; PATHWAY; DEGRADATION; INHIBITION; DERIVATIVES; BTK; IBRUTINIB; MK-2206; TARGET;
D O I
10.1016/j.ejmech.2022.114459
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
AKT and associated signaling pathways have been recognized as promising therapeutic targets for decades, and growing evidence indicates that inhibition or degradation of cellular AKT are viable strategies to treat cancer. Guided by an in silico modeling approach for rational linker design and based on our previous work in this field, we herein efficiently synthesized a small group of cereblon-recruiting AKT PROTAC molecules and identified a highly potent AKT degrader B4. Compared to the existing AKT degraders, B4 has a structurally unique AKT targeting warhead derived from the pyrazole-furan conjugated piperidine derivatives. It induces selective degradation of all three isoforms of AKT and exhibits efficacious anti-proliferation against several human hematological cancers. Notably, B4 demonstrates potent inhibition of AKT downstream signaling superior to its parental inhibitor. Together with its active analogs, B4 expands the arsenal of AKT chemical degraders as a valuable probe to uncover AKTs new functions and as a potential drug candidate to treat cancer.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia
    Kaneshige, Atsunori
    Bai, Longchuan
    Wang, Mi
    McEachern, Donna
    Meagher, Jennifer L.
    Xu, Renqi
    Kirchhoff, Paul D.
    Wen, Bo
    Sun, Duxin
    Stuckey, Jeanne A.
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (04) : 2717 - 2743
  • [22] Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong in vivo Antitumor Activity
    Yang, Lin
    Tu, Wenbin
    Huang, Liyue
    Miao, Bukeyan
    Kaneshige, Atsunori
    Jiang, Wei
    Leng, Lingying
    Wang, Meilin
    Wen, Bo
    Sun, Duxin
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (15) : 10761 - 10781
  • [23] Structure-Based Design of a Potent and Selective YTHDC1 Ligand
    Zalesak, Frantisek
    Nai, Francesco
    Herok, Marcin
    Bochenkova, Elena
    Bedi, Rajiv K.
    Li, Yaozong
    Errani, Francesco
    Caflisch, Amedeo
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (11) : 9516 - 9535
  • [24] Structure-Based Design of Potent and Selective CK1γ Inhibitors
    Huang, Hongbing
    Acquaviva, Lisa
    Berry, Virginia
    Bregman, Howard
    Chakka, Nagasree
    O'Connor, Anne
    DiMauro, Erin F.
    Dovey, Jennifer
    Epstein, Oleg
    Grubinska, Barbara
    Goldstein, Jon
    Gunaydin, Hakan
    Hua, Zihao
    Huang, Xin
    Huang, Liyue
    Human, Jason
    Long, Alex
    Newcomb, John
    Patel, Vinod F.
    Saffran, Doug
    Serafino, Randy
    Schneider, Steve
    Strathdee, Craig
    Tang, Jin
    Turci, Susan
    White, Ryan
    Yu, Violeta
    Zhao, Huilin
    Wilson, Cindy
    Martin, Matthew W.
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (12): : 1059 - 1064
  • [25] Structure-Based Design of Potent and Selective Ligands at the Four Adenosine Receptors
    Jespers, Willem
    Oliveira, Ana
    Prieto-Diaz, Ruben
    Majellaro, Maria
    Aqvist, Johan
    Sotelo, Eddy
    Gutierrez-de-Teran, Hugo
    MOLECULES, 2017, 22 (11):
  • [26] Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors
    Bhide, Rajeev S.
    Keon, Alec
    Weigelt, Carolyn
    Sack, John S.
    Schmidt, Robert J.
    Lin, Shuqun
    Xiao, Hai-Yun
    Spergel, Steven H.
    Kempson, James
    Pitts, William J.
    Carman, Julie
    Poss, Michael A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (21) : 4908 - 4913
  • [27] Structure-based library design and the discovery of a potent and selective mast cell β-tryptase inhibitor as an oral therapeutic agent
    Liang, Guyan
    Aldous, Suzanne
    Merriman, Gregory
    Levell, Julian
    Pribish, James
    Cairns, Jennifer
    Chen, Xin
    Maignan, Sebastien
    Mathieu, Magali
    Tsay, Joseph
    Sides, Keith
    Rebello, Sam
    Whitely, Brian
    Morize, Isabelle
    Pauls, Henry W.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (02) : 1049 - 1054
  • [28] Discovery of a Highly Potent and Selective BRD9 PROTAC Degrader Based on E3 Binder Investigation for the Treatment of Hematological Tumors
    Duan, Haiting
    Zhang, Jingyu
    Gui, Renzhao
    Lu, Yang
    Pang, Ao
    Chen, Beijing
    Shen, Liteng
    Yu, Hengyuan
    Li, Jia
    Xu, Tengfei
    Wang, Yuwei
    Yao, Xiaojun
    Zhang, Bo
    Lin, Nengming
    Dong, Xiaowu
    Zhou, Yubo
    Che, Jinxin
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (13) : 11326 - 11353
  • [29] Structure-Based Rational Design of a Phosphotriesterase
    Jackson, Colin J.
    Weir, Kahli
    Herlt, Anthony
    Khurana, Jeevan
    Sutherland, Tara D.
    Horne, Irene
    Easton, Christopher
    Russell, Robyn J.
    Scott, Colin
    Oakeshott, John G.
    APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2009, 75 (15) : 5153 - 5156
  • [30] Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers
    Li, Yujue
    Li, Jiaxuan
    Zhou, Haoxuan
    Liu, Chengyali
    Liu, Zi
    Ying, Binwu
    Xie, Yongmei
    Hu, Mingxing
    Gong, Youling
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 244